Table 2.
Description of the study participants categorized by androgen status.
| Control | Normo-androgenic PCOS | Hyperandrogenic PCOS | P-value | |
|---|---|---|---|---|
| N | 61 | 37 | 34 | |
| Age (year) | 32.28 ± 3.51 | 30.97 ± 2.78 | 31.32 ± 3.58 | 0.057a, 0.210b |
| BMI (kg/m2) | 23.28 ± 3.19 | 23.75 ± 3.52 | 24.79 ± 2.51 | 0.497a, 0.019b |
| Mannose (ng/mL) | 183.71 (141.97–236.08) | 228.90 (167.62–313.92) | 292.69 (221.73–462.26) | 0.010a, 0.001b |
| Total testosterone (nM) | 1.46 (1.04–1.91) | 1.91 (1.73–2.18) | 2.65 (2.35–3.31) | 0.001a, b |
| Free testosterone (nM) | 0.019(0.013–0.023) | 0.025 (0.017–0.029) | 0.031 (0.023–0.044) | 0.014a, 0.001b |
| SHBG (nM) | 54.31 (32.67–88.72) | 40.39 (25.65–56.89) | 31.05 (22.01–71.98) | 0.057a, 0.036b |
| DHEAS (nM) | 2825.69 (1675.75–4320.76) | 3379.62 (2518.11–4782.73) | 6859.96 (4460.21–9637.74) | 0.079a, 0.001b |
| AMH (pmol/L) | 23.21 (13.60–39.02) | 58.12 (44.84–87.93) | 62.76 (46.96–98.85) | 0.001a, b |
| FSH (IU/L) | 7.69 ± 3.46 | 6.23 ± 1.92 | 6.64 ± 1.94 | 0.021a, 0.105b |
| LH (IU/L) | 4.66 (3.43–6.54) | 11.32 (7.88–15.78) | 12.06 (6.04–16.20) | 0.001a, b |
| Estradiol (nM) | 0.18 ± 0.12 | 0.27 ± 0.15 | 0.23 ± 0.13 | 0.005a, 0.065b |
| Prolactin (ng/mL) | 11.55 ± 4.14 | 11.77 ± 7.58 | 10.64 ± 5.11 | 0.855a, 0.348b |
| TSH (μIU/mL) | 1.84 (1.42–2.82) | 2.23 (1.11–2.76) | 1.74 (1.19–2.44) | 0.626a, 0.235b |
| FPG (mM) | 5.05 ± 0.36 | 5.05 ± 0.38 | 5.06 ± 0.38 | 0.926a, 0.925b |
| FI (mIU/L) | 10.00 (8.05–14.10) | 9.90 (7.55–16.91) | 12.90 (8.45–15.85) | 0.676a, 0.122b |
| HOMA-IR | 2.66 ± 1.59 | 2.86 ± 1.69 | 2.98 ± 1.44 | 0.562a, 0.343b |
| QUICKI | 0.34 ± 0.03 | 0.34 ± 0.03 | 0.33 ± 0.03 | 0.755a, 0.279b |
| TC (mM) | 4.45 ± 0.70 | 4.57 ± 0.68 | 4.93 ± 0.72 | 0.415a, 0.002b |
| LDL-C (mM) | 2.72 ± 0.71 | 2.83 ± 0.55 | 2.91 ± 0.68 | 0.404a, 0.207b |
| HDL-C (mM) | 1.35 (1.13–1.64) | 1.19 (0.88–1.32) | 1.27 (1.05–1.48) | 0.003a, 0.207b |
| Triglycerides (mM) | 0.98 (0.64–1.38) | 1.19 (0.79–1.59) | 1.19 (0.84–2.33) | 0.182a, 0.022b |
BMI, body mass index; SHBG, sex hormone-binding globulin; DHEAS, dehydroepiandrosterone sulfate; AMH, anti-Müllerian hormone; FSH, follicle-stimulating hormone; LH, luteinizing hormone; TSH, thyroid-stimulating hormone; FPG, fasting plasma glucose; FI, fasting serum insulin; HOMA-IR, homeostasis model assessment of insulin resistance; QUICKI, quantitative insulin-sensitivity check index; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol. Mean ± standard deviation or median (interquartile range) are shown.
Comparing the normo-androgenic PCOS patients and controls after post-hoc test.
Comparing the hyperandrogenic PCOS patients and controls after post-hoc test.
P-values were adjusted for multiple testing using the Bonferroni method.